Yeah, in in terms of what else needs to be done in clinical trial design for PTCL I think uh trials uh need to be designed to focus on specific subtypes of PTCL and not just um enroll all PTCL as a whole. We now know that, you know, there are over. 30 different subtypes of PTCL and it's very heterogeneous, um, and each subtype can respond very differently to any one particular treatment. And so when we have trials that encompass all PTCL. Um, and you know, even though the, the sample size in that trial can be over 100 patients, uh, or could be more substantial, we're really unable to make meaningful conclusions for, uh, from, from a patient perspective because, uh, each, the sample size for each subtype of PTCL is so small. So I do think that that is the main um uh one of the main um priorities we need to, to consider when designing a trial. Um, the second I would say is trying to explore other settings for some of the, some of the drugs we have. Unfortunately, we have very few drugs in PTCL and You know, right now there is a big push um to, to test combinations of these drugs, but at the end of the day, we still have very few drugs and there will only be a few combinations of drugs that are, that are being studied, um. We know that PTCL uh is the duration of response with each drug or each regimen is short and so, you know, looking at Um, each drug or, or, um, or combination of drugs in various settings, whether it's maintenance after first line therapy, as a bridge to transplant, as a bridge to other novel therapies, um, as maintenance setting after aloe, um, looking or or focusing on. Um, looking at these other settings in terms of trying to, trying to keep patients, uh, and trying to keep patients in, in remission, I think is also, um, another important aspect of, of, uh, the clinical trial study designed for PTCL.
Presenter
